Pioneering transaction also marks first ever
cannabis oil import to Brazil
MARKHAM, ON, Aug. 8, 2017 /CNW/ - MedReleaf Corp. (TSX:
LEAF) (MedReleaf or the "Company"), North
America's first and only ISO 9001 and ICH-GMP certified
producer of cannabis-based pharmaceutical products, today announced
a milestone achievement with the completion of its first
international export. The transaction is also noteworthy as
the first ever import of medical cannabis oil to Brazil and serves as a demonstration of both
the Company's commitment to international growth and to
establishing its position as the leading source of cannabis-based
pharmaceutical products globally.
The export is being made to treat the symptoms of Sofia Langenbach, a child who carries the CDKL5
genetic syndrome – leading her to experience refractory epilepsy
and severe seizures which for her, has only been alleviated by the
use of medical cannabis. Her mother, Ms. Margarette Santos de Brito, currently president
of APEPI ("Support for Research and Medical Cannabis Patients"),
the first and largest Association of Cannabis patients in
Brazil, previously won a landmark
Brazilian court case to cultivate her own cannabis and has been one
of the leading activists advocating for the legalization of medical
cannabis in Brazil for many
years.
"We have been working with Margarette
Santos De Brito (president of Brazilian NGO APEPI), who has
been a tireless, high-profile public champion of medical cannabis
and whose daughter Sofia is in dire need of cannabis-based
pharmaceutical products to manage her symptoms." said Neil Closner, CEO of MedReleaf. "We are proud
that Ms. Santos and ANVISA, the Brazilian Government's National
Health Surveillance Agency, have put their faith in MedReleaf."
"This is an important step in achieving MedReleaf's goals of
ensuring that patients in need around the world receive the highest
quality cannabis-based pharmaceutical products available and in
realizing our long-term growth plans." continued Closner.
"I am very thankful we received this first import of MedReleaf's
medical grade cannabis oil for Sofia" said Ms. Santos.
About MedReleaf
MedReleaf sets The Medical Grade
Standard™ for cannabis in Canada and around the world. The first
and only ICH-GMP and ISO 9001 certified producer of cannabis-based
pharmaceutical products in North
America, MedReleaf is a R&D-driven company dedicated to
patient care, scientific innovation, research and advancing the
understanding of the therapeutic benefits of cannabis.
Sourced from around the world and perfected in one of two state of
the art facilities in Ontario,
MedReleaf delivers a variety of premium products to patients
seeking safe, consistent and effective medical cannabis.
For more information on MedReleaf, its products, research and
how the company is helping patients #livefree, please visit
MedReleaf.com or follow @medreleafcanada.
Forward Looking Statements
This press release contains "forward-looking information" within
the meaning of applicable Canadian securities legislation which are
based upon MedReleaf's current internal expectations, estimates,
projections, assumptions and beliefs and views of future events.
Forward-looking information can be identified by the use of
forward-looking terminology such as "expect", "likely", "may",
"will", "should", "intend", "anticipate", "potential", "proposed",
"estimate" and other similar words, including negative and
grammatical variations thereof, or statements that certain events
or conditions "may", "would" or "will" happen, or by discussions of
strategy. Forward-looking information include estimates, plans,
expectations, opinions, forecasts, projections, targets, guidance
or other statements that are not statements of fact.
Any forward-looking information speaks only as of the date on
which it is made, and, except as required by law, MedReleaf does
not undertake any obligation to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise. New factors emerge from
time to time, and it is not possible for MedReleaf to predict all
such factors. When considering these forward-looking statements,
readers should keep in mind the risk factors and other cautionary
statements in MedReleaf's Final Long Form Prospectus dated
May 30, 2017 and filed with the
applicable Canadian securities regulatory authorities on SEDAR
at www.sedar.com. The risk factors and other factors noted in
MedReleaf's Final Long Form Prospectus could cause actual events or
results to differ materially from those described in any
forward-looking information.
SOURCE MedReleaf Corp.